Ipratropium bromide: are patients treated with optimal therapy?

Area of Science:

• Pharmacology
• Respiratory Medicine
• Clinical Trials

Background:

• Stable chronic asthma requires effective bronchodilator therapy.
• Standard doses of ipratropium bromide may not be sufficient for all patients.
• Dose-response data for inhaled ipratropium bromide are crucial for optimizing treatment.

Purpose of the Study:

• To evaluate the dose-response relationship of ipratropium bromide in patients with stable chronic asthma.
• To compare the efficacy and duration of action of different ipratropium bromide doses.
• To assess the safety and tolerability of higher ipratropium bromide doses.

Main Methods:

• A double-blind, crossover, placebo-controlled study.
• 20 patients with stable chronic asthma participated.
• Administration of ipratropium bromide (40, 80, 200 micrograms) via metered dose inhaler.

Main Results:

• The 200 microgram dose of ipratropium bromide showed significantly greater peak effect and duration of action compared to the standard 40 microgram dose.
• Maximum spirometric response was observed within 24 hours post-inhalation.
• Higher doses were generally well-tolerated, with marked individual variations in response.

Conclusions:

• Higher doses of ipratropium bromide may offer enhanced bronchodilation and longer duration of action in chronic asthma.
• The study identifies patients likely to benefit from higher doses within 24 hours.
• Increased ipratropium bromide dosages may be clinically beneficial for patients unresponsive to standard treatment.